The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

Seniors have a 61% higher risk of stroke if their parents divorced when they were children or teenagers, researchers reported in a study published Wednesday in the journal PLOS One.

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

Monica Johnson, Psy.D., is a clinical psychologist ... approaches to treating a wide range of mental health issues such as depression, anxiety, trauma, and personality disorders.

Staff vacancies require corrections officers to work at least 16- or 24-hour shifts, and the mandatory overtime takes a toll.

To address a lack of psychiatric inpatient beds within Brazoria County, stakeholders from health care, education and local government are asking the 89th Texas Legislature to help fund the county’s ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

Morgan Stanley lowered the firm’s price target on Johnson & Johnson to $163 from $175 and keeps an Equal Weight rating on the shares ...